Day: August 12, 2025

Company Reaffirms FY 2025 Revenue Guidance Range of $111.0 Million to $113.0 Million, Representing 10% Year-Over-Year Growth at the Midpoint Company Reaffirms Expectation for ARR1 to Increase from $95.6 Million at the Beginning of 2025 to Approximately $110.0 Million at the Beginning of 2026 FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — SoundThinking, Inc. (Nasdaq: SSTI), a leading public safety technology company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial and Operational HighlightsRevenues decreased 4% to $25.9 million, compared to $27.0 million for the same quarter of 2024. Gross profit decreased 14% to $13.8 million (53% of revenues), compared to $16.1 million (60% of revenues) for the same quarter of 2024. GAAP net loss totaled $3.1 million, compared to...

Achieves Revenue and Gross Margin in Line With Expectations ASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) — Urgent.ly Inc. (Nasdaq: ULY) (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, today reported financial results for the second quarter ended June 30, 2025. “We are very pleased to report sequential quarterly revenue growth for the second quarter of 2025 compared to the first quarter of 2025. We also delivered a reduction in GAAP operating loss and non-GAAP operating loss ahead of our expectations, as we continue to make progress towards positive cash flow,” said Matt Booth, CEO of Urgently. “Our digitally native platform, which leverages A.I. and machine learning, has given us substantial operating scale in the market by creating predictive models to enhance performance...

Total Revenue of $68.1 million, an increase of approximately 400% quarter-over-quarter Net Income of $35.7 million, an increase of over 500% quarter-over-quarter Over 540% increase in quarterly production to a total of 21,052 Boe/d per day (50% oil) Record Adjusted EBITDA of $38.6 million, an increase of over 600% quarter-over-quarterHOUSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) — Prairie Operating Co. (Nasdaq: PROP) (the “Company,” “Prairie,” “we,” “our,” or “us”), an independent energy company engaged in the development and acquisition of oil, natural gas, and natural gas liquids (“NGL”) resources in the Denver-Julesburg (DJ) Basin – today announced its financial and operational results for the quarter ended June 30, 2025. RECENT KEY HIGHLIGHTSTotal revenue of $68.1 million, an increase of approximately 400% quarter-over-quarter. Record...

Second Quarter Results Strengthen Position as AI Leader in Roadway IntelligenceImproved Adjusted EBITDA: Substantially narrowed Adjusted EBITDA loss by $2 million for the six-month period. Operating Expense Reduction: Reduced operating expenses by 17% quarter over quarter and year over year, reflecting strong cost discipline. Quarterly Gross Revenue: Quarterly gross revenue of $12.4 million, showing the expected rebound from the prior quarter and resulting in revenue nearly flat year-over-year.      ATM Offering has been terminated as part of strategic capital initiatives.COLUMBIA, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ: REKR), a global leader in roadway intelligence, today announced its financial results for the three- and six-month periods ending June 30, 2025. “In Q2, we made significant...

Cepheus-1-36QRigetti’s Cepheus-1-36Q modular processor. Photo credit: Drew Bird PhotographyCepheus-1-36Q processor assemblyA single 9-qubit Rigetti chip being loaded into a mount for flip-chip bonding, the process used for assembling Rigetti’s Cepheus-1-36Q processor. Photo credit: Drew Bird PhotographyBERKELEY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Financial HighlightsTotal revenues for the three months ended June 30, 2025 were $1.8 million Total operating expenses for the three months ended June 30, 2025 were $20.4 million Operating loss for the three months ended June...

Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs Submitted a Marketing Authorisation Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C Company to host conference call and webcast TODAY, August 12, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the three and six months ended June 30, 2025. “This is an exciting time of growth for Zevra,” said Neil...

LOUISVILLE, Ky., Aug. 12, 2025 (GLOBE NEWSWIRE) — LogicMark, Inc. (OTC: LGMK) (the Company), a provider of personal safety, personal emergency response systems (PERS), health communications devices, and technology for the growing care and safety economy, today announced financial and operational results for the quarter ended June 30, 2025. Summary:           Revenues were $2.9 million in the second quarter of 2025, an increase of 22% compared with the second quarter of 2024. Gross Profit in the second quarter of 2025 improved 24% to $1.9 million compared with the prior year period. Gross margin improved to 67.5%, a 99 bp increase compared with the prior year period. Improved liquidity with cash and investments of $13.0 million, due to a successful capital raise earlier in the year, along with no long-term debt, as of June 30,...

– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q’25 – – Type 2a meeting with the FDA anticipated in 4Q’25– – Cash runway expected to support operations through FDA meeting and regulatory feedback – IRVINE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, announced its financial results for the second quarter ended June 30, 2025, and provided a business update. “We have made strong progress this quarter toward the major biosimilar development milestones laid out for the second half of 2025. We are poised to report...

Received FDA feedback on Pre-IND Briefing Document reinforcing Company’s intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease.Announced strategic research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases.Upfront payment of $12 million and ~$345 million in potential milestone paymentsRaised approximately $20 million through a public offering.BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease...

Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration with Almirall, with election of a second target focused on dermatological indications VANCOUVER, Wash. and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operating results for the quarter ended June 30, 2025. “The past few months have been a period of strong execution for Absci, and we are positioned to build on this momentum,” said Sean McClain, Founder and CEO. “ABS-101 is advancing through clinical trials, ABS-201 is on track to enter the...